The US Supreme Court’s much awaited decision in mid-June that naturally occurring genes cannot be patented immediately sent waves through the market for genetic testing. Within hours, competitors of Myriad Genetics, which had held a monopoly for nearly 2 decades on genetic testing for cancer-related mutations in the tumor-suppressing genes BRCA1 and BRCA2, began offering their own versions of the test for as little as $995, about one-third of the cost of Myriad’s test.
Kuehn BM. Supreme Court Rules Against Gene Patents. JAMA. 2013;310(4):357-359. doi:10.1001/jama.2013.8627